Dynamic quotes: Off
|
Company Description (as filed with the SEC)
Anika Therapeutics, Inc. (“Anika,” and together with its subsidiaries, the “Company,” “we,” “us,” or “our”) was incorporated in 1992 as a Massachusetts company. Anika develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (“HA”), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells. Anika Therapeutics, Inc.’s wholly-owned subsidiary, Anika Therapeutics S.r.l., has over 20 products currently commercialized, primarily in Europe. ... More ...
Analyst Info |
|
| Annual EPS Est: | $0.93 |
| Quarterly EPS Est: | 0.29 |
| PEG Ratio: | .01 |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research

